Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Race Oncology Ltd. ( (AU:RAC) ).
Racura Oncology will present new preclinical data on its (E,E)-bisantrene molecule at the American Association of Cancer Research Annual Meeting 2026 in San Diego, highlighting a mechanism that silences MYC gene expression by stabilising G-quadruplex DNA structures in the MYC promoter. The work, to be published in Cancer Research, shows that (E,E)-bisantrene binds the MYC G4 region with a 2:1 stoichiometry, suppresses MYC and other oncogenes across multiple cancer cell lines, and underpins the company’s ongoing Phase 1 and Phase 3 programmes of RC220 in lung cancer and acute myeloid leukemia, reinforcing its position in the emerging field of G4-targeting oncology therapeutics.
Using biophysical assays, NMR and molecular modelling, Racura’s team and collaborators demonstrated that (E,E)-bisantrene achieves G4 stabilisation and induces a transcriptomic profile similar to other G4-binding drugs such as pidnarulex. These findings strengthen the biological rationale for RC220 as a potential practice-changing therapy in MYC-driven tumours and may enhance Racura’s visibility among global oncology researchers and investors by aligning its pipeline with a validated, mechanism-based approach to suppressing key cancer growth regulators.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australian clinical-stage biotechnology company focused on developing small-molecule anticancer drugs. Its lead asset, RC220, is based on the (E,E)-bisantrene isomer and is being advanced in trials targeting MYC-driven malignancies such as EGFR-mutant non-small cell lung cancer and acute myeloid leukemia.
Average Trading Volume: 162,276
Technical Sentiment Signal: Buy
Current Market Cap: A$401.6M
See more insights into RAC stock on TipRanks’ Stock Analysis page.